On a consolidated basis, Aarti Drugs' net profit spurted 132.96% to Rs 75.27 crore on 21.07% increase in net sales to Rs 578.11 crore in Q2 September 2020 over Q2 September 2019.
Profit before tax (PBT) stood at Rs 97.12 crore, a 102% jump over Rs 47.87 crore reported in the same period last year. Total tax expense grew 40.5% year on year to Rs 21.85 crore in Q2 September 2020. The result was announced after market hours on Friday, 23 October 2020.
The board of the company has recommended an interim dividend of Rs 2.5 per equity share.
The board also passed an enabling resolution for raising upto Rs 350 crore by issuing equity shares or any other instruments or security including fully/partly convertible debentures or by way of a composite issue of non-convertible debentures through qualified institutions placement, private placement/public issue of equity/debt securities or through any other permissible mode.
Shares of Aarti Drugs fell 0.09% to Rs 748.75 on Friday.
Aarti Drugs is a pharmaceutical company. The company has a strong presence in the anti-diarrhea, anti-inflammatory therapeutic groups.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)